Akebia Therapeutics Says Vafseo Trial Meets Primary Endpoint in CKD Anemia
11:08 AM EST, 11/05/2026 (MT Newswires) -- Akebia Therapeutics (AKBA) said Thursday its Vocal trial
Related stories
Money Quote: True AI Panic — WSJ
"This is a true panic. This is 100% about the chip stocks and the potential slowdown in the AI trade."-Jay Hatfield, CEO at Infrastructure Capital Advisors, on the Nasdaq selloff T
L impact | EQUITY | Nov 05, 2026, 04:16 PM UTC
Bissinger, Oshman, Williams & Strasburger Earns Best Law Firms Honors
Houston firm recognized in 2027 guide in three practice areas HOUSTON--(BUSINESS WIRE)-- Trial firm
L impact | EQUITY | Nov 05, 2026, 04:16 PM UTC
UPDATE 3-Soccer-Portugal's Ronaldo announces international retirement
UPDATE 3-Soccer-Portugal's Ronaldo announces international retirement Ronaldo says he is stepping do
L impact | EQUITY | Nov 05, 2026, 04:16 PM UTC
Nordic business leaders plot to keep companies in home markets
By Marie MannesA new Nordic business alliance backed by Sweden's Wallenberg and Finland's Herlin families plans to enlist seven or more "anchor partners" for an independently manag
L impact | EQUITY | Nov 05, 2026, 04:15 PM UTC
POLONIA Rate rises 0.08 pp.
L impact | EQUITY | Nov 05, 2026, 04:15 PM UTC
BRIEF-Polenergia Prelim. 9-months EBITDA At 332.5 Million Zlotys
BRIEF-Polenergia Prelim. 9-months EBITDA At 332.5 Million Zlotys Nov 5 (Reuters) - Polenergia SA PEP
L impact | EQUITY | Nov 05, 2026, 04:15 PM UTC